112 related articles for article (PubMed ID: 10744937)
1. Overexpression of p53 protein in gallbladder carcinoma in North India.
Misra S; Chaturvedi A; Goel MM; Mehrotra R; Sharma ID; Srivastava AN; Misra NC
Eur J Surg Oncol; 2000 Mar; 26(2):164-7. PubMed ID: 10744937
[TBL] [Abstract][Full Text] [Related]
2. Aberrant p53 expression and the development of gallbladder carcinoma and adenoma.
Wang SN; Chung SC; Tsai KB; Chai CY; Chang WT; Kuo KK; Chen JS; Lee KT
Kaohsiung J Med Sci; 2006 Feb; 22(2):53-9. PubMed ID: 16568721
[TBL] [Abstract][Full Text] [Related]
3. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions.
Ajiki T; Onoyama H; Yamamoto M; Asaka K; Fujimori T; Maeda S; Saitoh Y
Hepatogastroenterology; 1996; 43(9):521-6. PubMed ID: 8799388
[TBL] [Abstract][Full Text] [Related]
4. The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases.
da Rocha AO; Coutinho LM; Scholl JG; Leboutte LD
Hepatogastroenterology; 2004; 51(59):1310-4. PubMed ID: 15362740
[TBL] [Abstract][Full Text] [Related]
5. [P53 gene mutation in gallbladder cancer].
Roa I; Melo A; Roa J; Araya J; Villaseca M; de Aretxabala X
Rev Med Chil; 2000 Mar; 128(3):251-8. PubMed ID: 10962865
[TBL] [Abstract][Full Text] [Related]
6. [Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa].
Billo P; Marchegiani C; Capella C; Sessa F
Pathologica; 2000 Aug; 92(4):249-56. PubMed ID: 11029885
[TBL] [Abstract][Full Text] [Related]
7. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile.
Yokoyama N; Hitomi J; Watanabe H; Ajioka Y; Pruyas M; Serra I; Shirai Y; Hatakeyama K
Cancer Epidemiol Biomarkers Prev; 1998 Apr; 7(4):297-301. PubMed ID: 9568784
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of p53 expression and its correlation with clinical response of radiotherapy in nasopharyngeal carcinoma.
Ho KY; Kuo WR; Chai CY; Tsai SM; Sheu SH; Wu SC; Juan KH
Laryngoscope; 2001 Jan; 111(1):131-6. PubMed ID: 11192881
[TBL] [Abstract][Full Text] [Related]
9. P53 overexpression in nasopharyngeal carcinoma.
Agaoglu FY; Dizdar Y; Dogan O; Alatli C; Ayan I; Savci N; Tas S; Dalay N; Altun M
In Vivo; 2004; 18(5):555-60. PubMed ID: 15523893
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions.
Parwani AV; Geradts J; Caspers E; Offerhaus GJ; Yeo CJ; Cameron JL; Klimstra DS; Maitra A; Hruban RH; Argani P
Mod Pathol; 2003 Apr; 16(4):299-308. PubMed ID: 12692194
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations involved in the development of gallbladder carcinomas from Greek patients.
Saetta A; Lazaris AC; Michalopoulos NV; Davaris PS
Hepatogastroenterology; 2001; 48(41):1284-8. PubMed ID: 11677947
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction.
Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F
J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma.
Kalekou H; Miliaras D
J Gastroenterol Hepatol; 2004 Jul; 19(7):812-8. PubMed ID: 15209630
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
17. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical markers in the study of gallbladder premalignant lesions and cancer.
Stancu M; Căruntu ID; Sajin M; Giuşcă S; Bădescu A; Dobrescu G
Rev Med Chir Soc Med Nat Iasi; 2007; 111(3):734-43. PubMed ID: 18293709
[TBL] [Abstract][Full Text] [Related]
20. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Tomoyose T; Takano H; Funaki K; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2005 Nov; 34(10):602-7. PubMed ID: 16202080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
